Skip to main content
Erschienen in: Current Neurology and Neuroscience Reports 9/2016

01.09.2016 | Neuro-Oncology (LE Abrey, Section Editor)

Chemotherapy-Related Neurotoxicity

verfasst von: Sophie Taillibert, Emilie Le Rhun, Marc C. Chamberlain

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 9/2016

Einloggen, um Zugang zu erhalten

Abstract

Chemotherapy may have detrimental effects on either the central or peripheral nervous system. Central nervous system neurotoxicity resulting from chemotherapy manifests as a wide range of clinical syndromes including acute, subacute, and chronic encephalopathies, posterior reversible encephalopathy, acute cerebellar dysfunction, chronic cognitive impairment, myelopathy, meningitis, and neurovascular syndromes. These clinical entities vary by causative agent, degree of severity, evolution, and timing of occurrence. In the peripheral nervous system, chemotherapy-induced peripheral neuropathy (CIPN) and myopathy are the two main complications of chemotherapy. CIPN is the most common complication, and the majority manifest as a dose-dependent length-dependent sensory axonopathy. In severe cases of CIPN, the dose of chemotherapy is reduced, the administration delayed, or the treatment discontinued. Few treatments are available for CIPN and based on meta-analysis, duloxetine is the preferred symptomatic treatment. Myopathy due to corticosteroid use is the most frequent cause of muscle disorders in patients with cancer.
Literatur
1.••
Zurück zum Zitat Ganz PA, Dougherty PM. Painful hands and feet after cancer treatment: inflammation affecting the mind-body connection. J Clin Oncol. 2016;34:649–52. An updated expert opinion on recent advances regarding chemotherapy –related neurotoxicity, underscoring the important role of inflammation in cognitive dysfunction, and peripheral neuropathy, both linked to neuroinflammation as well as genetic susceptibility to persistent inflammation and behavioral symptoms. The authors also highlight that the symptoms of chemotherapy neurotoxicity can now be measured with a wide variety of well-validated self-report tools i.e. patient-reported outcomes.PubMedCrossRef Ganz PA, Dougherty PM. Painful hands and feet after cancer treatment: inflammation affecting the mind-body connection. J Clin Oncol. 2016;34:649–52. An updated expert opinion on recent advances regarding chemotherapy –related neurotoxicity, underscoring the important role of inflammation in cognitive dysfunction, and peripheral neuropathy, both linked to neuroinflammation as well as genetic susceptibility to persistent inflammation and behavioral symptoms. The authors also highlight that the symptoms of chemotherapy neurotoxicity can now be measured with a wide variety of well-validated self-report tools i.e. patient-reported outcomes.PubMedCrossRef
2.•
Zurück zum Zitat Nudelman KN, McDonald BC, Wang Y, et al. Cerebral perfusion and gray matter changes associated with chemotherapy-induced peripheral neuropathy. J Clin Oncol. 2016;34:677–83. Longitudinal relationship between chemotherapy-induced peripheral neuropathy (CIPN) symptoms and brain perfusion changes in patients with breast cancer. CIPN symptoms were positively associated with cerebral perfusion in the right superior frontal gyrus and cingulate gyrus, regions associated with pain processing.PubMedCrossRef Nudelman KN, McDonald BC, Wang Y, et al. Cerebral perfusion and gray matter changes associated with chemotherapy-induced peripheral neuropathy. J Clin Oncol. 2016;34:677–83. Longitudinal relationship between chemotherapy-induced peripheral neuropathy (CIPN) symptoms and brain perfusion changes in patients with breast cancer. CIPN symptoms were positively associated with cerebral perfusion in the right superior frontal gyrus and cingulate gyrus, regions associated with pain processing.PubMedCrossRef
3.
Zurück zum Zitat Magge RS, DeAngelis LM. The double-edged sword: neurotoxicity of chemotherapy. Blood Rev. 2015;29:93–100.PubMedCrossRef Magge RS, DeAngelis LM. The double-edged sword: neurotoxicity of chemotherapy. Blood Rev. 2015;29:93–100.PubMedCrossRef
5.
Zurück zum Zitat Hansen N. Drug-induced encephalopathy. In: Tanasescu R, editor. Miscellanea on encephalopathies—a second look. InTech, 2012. pp. 39–60. Hansen N. Drug-induced encephalopathy. In: Tanasescu R, editor. Miscellanea on encephalopathies—a second look. InTech, 2012. pp. 39–60.
6.
Zurück zum Zitat DeAngelis LM, Posner JB. Side effects of chemotherapy. In: Neurologic complications of cancer, 2nd. New York, Oxford University Press; 2009. p. 447. DeAngelis LM, Posner JB. Side effects of chemotherapy. In: Neurologic complications of cancer, 2nd. New York, Oxford University Press; 2009. p. 447.
7.
Zurück zum Zitat David KA, Picus J. Evaluating risk factors for the development of ifosfamide encephalopathy. Am J Clin Oncol. 2005;28:277–80.PubMedCrossRef David KA, Picus J. Evaluating risk factors for the development of ifosfamide encephalopathy. Am J Clin Oncol. 2005;28:277–80.PubMedCrossRef
8.
Zurück zum Zitat Hansen H. Aprepitant-associated ifosfamide neurotoxicity. J Oncol Pharm Pract. 2010;16:137–8.CrossRef Hansen H. Aprepitant-associated ifosfamide neurotoxicity. J Oncol Pharm Pract. 2010;16:137–8.CrossRef
9.
Zurück zum Zitat Ames B, Lewis LD, Chaffee S, et al. Ifosfamide-induced encephalopathy and movement disorder. Pediatr Blood Cancer. 2010;54:624–6.PubMed Ames B, Lewis LD, Chaffee S, et al. Ifosfamide-induced encephalopathy and movement disorder. Pediatr Blood Cancer. 2010;54:624–6.PubMed
10.
Zurück zum Zitat Savica R, Rabinstein AA, Josephs KA. Ifosfamide associated myoclonus-encephalopathy syndrome. J Neurol. 2011;258:1729–31.PubMedCrossRef Savica R, Rabinstein AA, Josephs KA. Ifosfamide associated myoclonus-encephalopathy syndrome. J Neurol. 2011;258:1729–31.PubMedCrossRef
11.
Zurück zum Zitat Nott L, Price TJ, Pittman K, et al. Hyperammonemia encephalopathy: an important cause of neurological deterioration following chemotherapy. Leuk Lymphoma. 2007;48:1702–11.PubMedCrossRef Nott L, Price TJ, Pittman K, et al. Hyperammonemia encephalopathy: an important cause of neurological deterioration following chemotherapy. Leuk Lymphoma. 2007;48:1702–11.PubMedCrossRef
12.
Zurück zum Zitat Bhojwani D, Sabin ND, Pei D, et al. Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol. 2014;32:949–59.PubMedPubMedCentralCrossRef Bhojwani D, Sabin ND, Pei D, et al. Methotrexate-induced neurotoxicity and leukoencephalopathy in childhood acute lymphoblastic leukemia. J Clin Oncol. 2014;32:949–59.PubMedPubMedCentralCrossRef
13.
Zurück zum Zitat Soussain C, Ricard D, Fike JR, Mazeron JJ, Psimaras D, Delattre JY. CNS complications of radiotherapy and chemotherapy. Lancet. 2009;374(9701):1639–51.PubMedCrossRef Soussain C, Ricard D, Fike JR, Mazeron JJ, Psimaras D, Delattre JY. CNS complications of radiotherapy and chemotherapy. Lancet. 2009;374(9701):1639–51.PubMedCrossRef
14.
Zurück zum Zitat Wefel JS, Saleeba AK, Buzdar AU, et al. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer. 2010;116:3348–56.PubMedCrossRef Wefel JS, Saleeba AK, Buzdar AU, et al. Acute and late onset cognitive dysfunction associated with chemotherapy in women with breast cancer. Cancer. 2010;116:3348–56.PubMedCrossRef
15.
Zurück zum Zitat Ahles TA, Saykin AJ, McDonald BC, et al. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol. 2010;28:4434–40.PubMedPubMedCentralCrossRef Ahles TA, Saykin AJ, McDonald BC, et al. Longitudinal assessment of cognitive changes associated with adjuvant treatment for breast cancer: impact of age and cognitive reserve. J Clin Oncol. 2010;28:4434–40.PubMedPubMedCentralCrossRef
16.
Zurück zum Zitat Jim HS, Phillips KM, Chait S, et al. Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol. 2012;30:3578–87.PubMedPubMedCentralCrossRef Jim HS, Phillips KM, Chait S, et al. Meta-analysis of cognitive functioning in breast cancer survivors previously treated with standard-dose chemotherapy. J Clin Oncol. 2012;30:3578–87.PubMedPubMedCentralCrossRef
17.
Zurück zum Zitat Moore HCF. An overview of chemotherapy-related cognitive dysfunction, or ‘chemobrain’. Oncology (Williston Park). 2014;28:797–804. Moore HCF. An overview of chemotherapy-related cognitive dysfunction, or ‘chemobrain’. Oncology (Williston Park). 2014;28:797–804.
18.
Zurück zum Zitat Ganz PA. Cancer treatment and cognitive function: chemotherapy is not the only culprit. Oncology (Williston Park). 2014;28(9):804–6. Ganz PA. Cancer treatment and cognitive function: chemotherapy is not the only culprit. Oncology (Williston Park). 2014;28(9):804–6.
19.
Zurück zum Zitat Ahles TA, Root JC, Ryan EL. Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. J Clin Oncol. 2012;30:3675–86.PubMedPubMedCentralCrossRef Ahles TA, Root JC, Ryan EL. Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. J Clin Oncol. 2012;30:3675–86.PubMedPubMedCentralCrossRef
20.
Zurück zum Zitat Vardy JL, Dhillon HM, Pond GR, et al. Cognitive function in patients with colorectal cancer who do and do not receive chemotherapy: a prospective, longitudinal, controlled study. J Clin Oncol. 2015;33:4085–93.PubMedCrossRef Vardy JL, Dhillon HM, Pond GR, et al. Cognitive function in patients with colorectal cancer who do and do not receive chemotherapy: a prospective, longitudinal, controlled study. J Clin Oncol. 2015;33:4085–93.PubMedCrossRef
21.
Zurück zum Zitat Ahles TA, Saykin AJ, Noll WW, et al. The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology. 2003;12:612–9.PubMedCrossRef Ahles TA, Saykin AJ, Noll WW, et al. The relationship of APOE genotype to neuropsychological performance in long-term cancer survivors treated with standard dose chemotherapy. Psychooncology. 2003;12:612–9.PubMedCrossRef
22.
Zurück zum Zitat McDonald BC, Conroy SK, Smith DJ, et al. Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: a replication and extension study. Brain Behav Immun. 2013;30(Suppl):S117–25.PubMedCrossRef McDonald BC, Conroy SK, Smith DJ, et al. Frontal gray matter reduction after breast cancer chemotherapy and association with executive symptoms: a replication and extension study. Brain Behav Immun. 2013;30(Suppl):S117–25.PubMedCrossRef
23.
Zurück zum Zitat Small BJ, Rawson KS, Walsh E, et al. Catechol-O-methyltransferase genotype modulates cancer treatment-related cognitive deficits in breast cancer survivors. Cancer. 2011;117:1369–76.PubMedCrossRef Small BJ, Rawson KS, Walsh E, et al. Catechol-O-methyltransferase genotype modulates cancer treatment-related cognitive deficits in breast cancer survivors. Cancer. 2011;117:1369–76.PubMedCrossRef
24.
25.
Zurück zum Zitat Kesler S, Janelsins M, Koovakkattu D, et al. Reduced hippocampal volume and verbal memory performance associated with interleukin-6 and tumor necrosis factor-alpha levels in chemotherapy-treated breast cancer survivors. Brain Behav Immun. 2013;30(Suppl):S109–16.PubMedCrossRef Kesler S, Janelsins M, Koovakkattu D, et al. Reduced hippocampal volume and verbal memory performance associated with interleukin-6 and tumor necrosis factor-alpha levels in chemotherapy-treated breast cancer survivors. Brain Behav Immun. 2013;30(Suppl):S109–16.PubMedCrossRef
26.•
Zurück zum Zitat Ganz PA, Bower JE, Kwan L, et al. Does tumor necrosis factor-alpha (TNFalpha) play a role in post-chemotherapy cerebral dysfunction? Brain Behav Immun. 2013;30:S99–108. An exploration of possible mechanisms associated with post-treatment cognitive dysfunction among breast cancer survivors. Cognitive complaints, neuropsychological (NP) test performance, markers of inflammation, and brain imaging were performed. Onlyserum TNF levels was significantly correlated with increased memory complaints and with relatively diminished brain metabolism in the inferior frontal cortex.PubMedCrossRef Ganz PA, Bower JE, Kwan L, et al. Does tumor necrosis factor-alpha (TNFalpha) play a role in post-chemotherapy cerebral dysfunction? Brain Behav Immun. 2013;30:S99–108. An exploration of possible mechanisms associated with post-treatment cognitive dysfunction among breast cancer survivors. Cognitive complaints, neuropsychological (NP) test performance, markers of inflammation, and brain imaging were performed. Onlyserum TNF levels was significantly correlated with increased memory complaints and with relatively diminished brain metabolism in the inferior frontal cortex.PubMedCrossRef
27.
Zurück zum Zitat Deprez S, Amant F, Smeets A, et al. Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. J Clin Oncol. 2012;30:274–81.PubMedCrossRef Deprez S, Amant F, Smeets A, et al. Longitudinal assessment of chemotherapy-induced structural changes in cerebral white matter and its correlation with impaired cognitive functioning. J Clin Oncol. 2012;30:274–81.PubMedCrossRef
28.••
Zurück zum Zitat Deprez S, Vandenbulcke M, Peeters R, et al. Longitudinal assessment of chemotherapy-induced alterations in brain activations during multitasking and its relation with cognitive complaints. J Clin Oncol. 2014;32:20131–8. Evidence for a relationship between longitudinal changes in cognitive complaints and changes in brain activation after chemotherapy.CrossRef Deprez S, Vandenbulcke M, Peeters R, et al. Longitudinal assessment of chemotherapy-induced alterations in brain activations during multitasking and its relation with cognitive complaints. J Clin Oncol. 2014;32:20131–8. Evidence for a relationship between longitudinal changes in cognitive complaints and changes in brain activation after chemotherapy.CrossRef
29.
Zurück zum Zitat de Ruiter MB, Reneman L, Boogerd W, et al. Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging. Hum Brain Mapp. 2012;33:2971–83.PubMedCrossRef de Ruiter MB, Reneman L, Boogerd W, et al. Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging. Hum Brain Mapp. 2012;33:2971–83.PubMedCrossRef
30.
Zurück zum Zitat de Ruiter MB, Reneman L, Boogerd W, et al. Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Hum Brain Mapp. 2011;32:1206–19.PubMedCrossRef de Ruiter MB, Reneman L, Boogerd W, et al. Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Hum Brain Mapp. 2011;32:1206–19.PubMedCrossRef
31.
Zurück zum Zitat McDonald BC, Conroy SK, Ahles TA, et al. Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study. Breast Cancer Res Treat. 2010;123:819–28.PubMedPubMedCentralCrossRef McDonald BC, Conroy SK, Ahles TA, et al. Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study. Breast Cancer Res Treat. 2010;123:819–28.PubMedPubMedCentralCrossRef
32.
Zurück zum Zitat Ercoli LM, Castellon SA, Hunter AM, et al. Assessment of the feasibility of a rehabilitation intervention program for breast cancer survivors with cognitive complaints. Brain Imaging Behav. 2013;7:543–53.PubMedCrossRef Ercoli LM, Castellon SA, Hunter AM, et al. Assessment of the feasibility of a rehabilitation intervention program for breast cancer survivors with cognitive complaints. Brain Imaging Behav. 2013;7:543–53.PubMedCrossRef
33.
Zurück zum Zitat Ercoli LM, Castellon S, Petersen L, et al. Cognitive rehabilitation group intervention for breast cancer survivors: results of a randomized clinical trial. International Cancer and Cognition Task Force Meeting; Seattle, WA 2014. Ercoli LM, Castellon S, Petersen L, et al. Cognitive rehabilitation group intervention for breast cancer survivors: results of a randomized clinical trial. International Cancer and Cognition Task Force Meeting; Seattle, WA 2014.
34.
Zurück zum Zitat Schuurs A, Green HJ. A feasibility study of group cognitive rehabilitation for cancer survivors: enhancing cognitive function and quality of life. Psycho-Oncology. 2013;22:1043–9.PubMedCrossRef Schuurs A, Green HJ. A feasibility study of group cognitive rehabilitation for cancer survivors: enhancing cognitive function and quality of life. Psycho-Oncology. 2013;22:1043–9.PubMedCrossRef
35.
Zurück zum Zitat Cherrier MM, Anderson K, David D, et al. A randomized trial of cognitive rehabilitation in cancer survivors. Life Sci. 2013;93:617–22.PubMedCrossRef Cherrier MM, Anderson K, David D, et al. A randomized trial of cognitive rehabilitation in cancer survivors. Life Sci. 2013;93:617–22.PubMedCrossRef
36.
Zurück zum Zitat Hunter AM, Kwan L, Ercoli LM, et al. Quantitative electroencephalography biomarkers of cognitive complaints after adjuvant therapy in breast cancer survivors: a pilot study. Psycho-Oncology. 2014;23:713–5.PubMedCrossRef Hunter AM, Kwan L, Ercoli LM, et al. Quantitative electroencephalography biomarkers of cognitive complaints after adjuvant therapy in breast cancer survivors: a pilot study. Psycho-Oncology. 2014;23:713–5.PubMedCrossRef
37.
Zurück zum Zitat Moore HF, Parsons M, Yue G, et al. Electroencephalogram power changes as a correlate of chemotherapy-associated fatigue and cognitive dysfunction. Support Care Cancer. 2014;22:2127–31.PubMedCrossRef Moore HF, Parsons M, Yue G, et al. Electroencephalogram power changes as a correlate of chemotherapy-associated fatigue and cognitive dysfunction. Support Care Cancer. 2014;22:2127–31.PubMedCrossRef
38.
Zurück zum Zitat Herzig RH, Hines, Herzig GP, et al. Cerebellar toxicity with high-dose cytosine arabinoside. J Clin Oncol. 1987;5:927–32.PubMed Herzig RH, Hines, Herzig GP, et al. Cerebellar toxicity with high-dose cytosine arabinoside. J Clin Oncol. 1987;5:927–32.PubMed
39.
Zurück zum Zitat Chamberlain MC. Neurotoxicity of intra-CSF liposomal cytarabine (DepoCyt) administered for the treatment of leptomeningeal metastases: a retrospective case series. J Neurooncol. 2012;109:143–8.PubMedCrossRef Chamberlain MC. Neurotoxicity of intra-CSF liposomal cytarabine (DepoCyt) administered for the treatment of leptomeningeal metastases: a retrospective case series. J Neurooncol. 2012;109:143–8.PubMedCrossRef
40.
Zurück zum Zitat Chamberlain MC, Glantz MJ. Re: neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood. 2007;110:1698–9.PubMedCrossRef Chamberlain MC, Glantz MJ. Re: neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia. Blood. 2007;110:1698–9.PubMedCrossRef
41.
Zurück zum Zitat Chamberlain MC, Kormanik PA, Barba D. Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurg. 1997;87:694–9.PubMedCrossRef Chamberlain MC, Kormanik PA, Barba D. Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases. J Neurosurg. 1997;87:694–9.PubMedCrossRef
42.
Zurück zum Zitat Zairi F, Le Rhun E, Bertrand N, Boulanger T, Taillibert S, Aboukais R, et al. Complications related to the use of an intraventricular access device for the treatment of leptomeningeal metastases from solid tumor: a single centre experience in 112 patients. J Neurooncol. 2015;124(2):317–23.PubMedCrossRef Zairi F, Le Rhun E, Bertrand N, Boulanger T, Taillibert S, Aboukais R, et al. Complications related to the use of an intraventricular access device for the treatment of leptomeningeal metastases from solid tumor: a single centre experience in 112 patients. J Neurooncol. 2015;124(2):317–23.PubMedCrossRef
43.
Zurück zum Zitat Pruitt AA. Nervous system infections in patients with cancer. Neurol Clin N Am. 2003;21:193–219.CrossRef Pruitt AA. Nervous system infections in patients with cancer. Neurol Clin N Am. 2003;21:193–219.CrossRef
44.
Zurück zum Zitat Rosenfeld MS, Pruitt A. Neurologic complications of bone marrow, stem cell, and organ transplantation in patients with cancer. Semin Oncol. 2006;33:352–61.PubMedCrossRef Rosenfeld MS, Pruitt A. Neurologic complications of bone marrow, stem cell, and organ transplantation in patients with cancer. Semin Oncol. 2006;33:352–61.PubMedCrossRef
45.
Zurück zum Zitat Li SH, Chen WH, Tang Y, Rau KM, Chen YY, Huang TL, et al. Incidence of ischemic stroke post-chemotherapy: a retrospective review of 10,963 patients. Clin Neurol Neurosurg. 2006;108(2):150–6.PubMedCrossRef Li SH, Chen WH, Tang Y, Rau KM, Chen YY, Huang TL, et al. Incidence of ischemic stroke post-chemotherapy: a retrospective review of 10,963 patients. Clin Neurol Neurosurg. 2006;108(2):150–6.PubMedCrossRef
46.
Zurück zum Zitat Hunault-Berger M, Chevallier P, Delain M, et al. Changes in antithrombin and fi brinogen levels during induction chemotherapy with l-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the capelal study. Haematologica. 2008;93:1488–94.PubMedCrossRef Hunault-Berger M, Chevallier P, Delain M, et al. Changes in antithrombin and fi brinogen levels during induction chemotherapy with l-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the capelal study. Haematologica. 2008;93:1488–94.PubMedCrossRef
47.
Zurück zum Zitat Carreras E, Cahn JY, Puozzo C, et al. Influence on Busilvex pharmacokinetics of clonazepam compared to previous phenytoin historical data. Anticancer Res. 2010;30:2977–84.PubMed Carreras E, Cahn JY, Puozzo C, et al. Influence on Busilvex pharmacokinetics of clonazepam compared to previous phenytoin historical data. Anticancer Res. 2010;30:2977–84.PubMed
48.
Zurück zum Zitat Masci G, Magagnoli M, Gullo G, et al. Herpes infections in breast cancer patients treated with adjuvant chemotherapy. Oncology. 2006;71:164–7.PubMedCrossRef Masci G, Magagnoli M, Gullo G, et al. Herpes infections in breast cancer patients treated with adjuvant chemotherapy. Oncology. 2006;71:164–7.PubMedCrossRef
49.
Zurück zum Zitat Teh HS, Fadilah SAW, Leong CF. Transverse myelopathy following intrathecal administration of chemotherapy. Singap Med. 2007;48:e46–9. Teh HS, Fadilah SAW, Leong CF. Transverse myelopathy following intrathecal administration of chemotherapy. Singap Med. 2007;48:e46–9.
50.
Zurück zum Zitat Shintaku M, Toyooka N, Koyama T, Teraoka S, Tsudo M. Methotrexate myelopathy with extensive transverse necrosis: report of an autopsy case. Neuropathol Off J Jpn Soc Neuropathol. 2014;34:547–53.CrossRef Shintaku M, Toyooka N, Koyama T, Teraoka S, Tsudo M. Methotrexate myelopathy with extensive transverse necrosis: report of an autopsy case. Neuropathol Off J Jpn Soc Neuropathol. 2014;34:547–53.CrossRef
51.
Zurück zum Zitat Cachia D, Kamiya-Matsuoka C, Pinnix CC, et al. Myelopathy following intrathecal chemotherapy in adults: a single institution experience. J Neurooncol. 2015;122:391–8.PubMedPubMedCentralCrossRef Cachia D, Kamiya-Matsuoka C, Pinnix CC, et al. Myelopathy following intrathecal chemotherapy in adults: a single institution experience. J Neurooncol. 2015;122:391–8.PubMedPubMedCentralCrossRef
52.
53.
Zurück zum Zitat Ackermann R, Semmler A, Maurer GD, et al. Methotrexate-induced myelopathy responsive to substitution of multiple folate metabolites. J Neurooncol. 2010;97:425–7.PubMedCrossRef Ackermann R, Semmler A, Maurer GD, et al. Methotrexate-induced myelopathy responsive to substitution of multiple folate metabolites. J Neurooncol. 2010;97:425–7.PubMedCrossRef
54.
Zurück zum Zitat Tisi MC, Ausoni G, Vita MG, et al. Clinical reversible myelopathy in T-cell lymphoblastic lymphoma treated with nelarabine and radiotherapy: report of a case and review of literature of an increasing complication. Mediterr J Hematol Infect Dis. 2015;7:e2015025.PubMedPubMedCentralCrossRef Tisi MC, Ausoni G, Vita MG, et al. Clinical reversible myelopathy in T-cell lymphoblastic lymphoma treated with nelarabine and radiotherapy: report of a case and review of literature of an increasing complication. Mediterr J Hematol Infect Dis. 2015;7:e2015025.PubMedPubMedCentralCrossRef
55.
Zurück zum Zitat Gollard RP, Selco S. Irreversible myelopathy associated with nelarabine in T-cell acute lymphoblastic leukemia. J Clin Oncol. 2013;31:327–31.CrossRef Gollard RP, Selco S. Irreversible myelopathy associated with nelarabine in T-cell acute lymphoblastic leukemia. J Clin Oncol. 2013;31:327–31.CrossRef
56.
Zurück zum Zitat Vagace JM, Caceres-Marzal C, Jimenez M, et al. Methotrexate-induced subacute neurotoxicity in a child with acute lymphoblastic leukemia carrying genetic polymorphisms related to folate homeostasis. Am J Hematol. 2011;86:98–101.PubMedCrossRef Vagace JM, Caceres-Marzal C, Jimenez M, et al. Methotrexate-induced subacute neurotoxicity in a child with acute lymphoblastic leukemia carrying genetic polymorphisms related to folate homeostasis. Am J Hematol. 2011;86:98–101.PubMedCrossRef
57.
Zurück zum Zitat Afshar M, Birnbaum D, Golden C. Review of dextromethorphan administration in 18 patients with subacute methotrexate central nervous system toxicity. Pediatr Neurol. 2014;50:625–9.PubMedCrossRef Afshar M, Birnbaum D, Golden C. Review of dextromethorphan administration in 18 patients with subacute methotrexate central nervous system toxicity. Pediatr Neurol. 2014;50:625–9.PubMedCrossRef
58.
Zurück zum Zitat Küpfer A, Aeschlimann C, Cerny T. Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy. Eur J Clin Pharmacol. 1996;50(4):249–52.PubMedCrossRef Küpfer A, Aeschlimann C, Cerny T. Methylene blue and the neurotoxic mechanisms of ifosfamide encephalopathy. Eur J Clin Pharmacol. 1996;50(4):249–52.PubMedCrossRef
59.
Zurück zum Zitat Takimoto CH, Lu ZH, Zhang R, et al. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res. 1996;2:477–81.PubMed Takimoto CH, Lu ZH, Zhang R, et al. Severe neurotoxicity following 5-fluorouracil-based chemotherapy in a patient with dihydropyrimidine dehydrogenase deficiency. Clin Cancer Res. 1996;2:477–81.PubMed
60.
Zurück zum Zitat Fugate JE, Claassen DO, Cloft HJ, et al. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc. 2010;85:427–32.PubMedPubMedCentralCrossRef Fugate JE, Claassen DO, Cloft HJ, et al. Posterior reversible encephalopathy syndrome: associated clinical and radiologic findings. Mayo Clin Proc. 2010;85:427–32.PubMedPubMedCentralCrossRef
61.
Zurück zum Zitat Kastrup O, Gerwig M, Frings M, Diener HC. Posterior reversible encephalopathy syndrome (PRES): electroencephalographic findings and seizure patterns. J Neurol. 2012;259:1383–9.PubMedCrossRef Kastrup O, Gerwig M, Frings M, Diener HC. Posterior reversible encephalopathy syndrome (PRES): electroencephalographic findings and seizure patterns. J Neurol. 2012;259:1383–9.PubMedCrossRef
62.
Zurück zum Zitat Covarrubias DJ, Luetmer PH, Campeau NG. Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images. AJNR Am J Neuroradiol. 2002;23:1038–48.PubMed Covarrubias DJ, Luetmer PH, Campeau NG. Posterior reversible encephalopathy syndrome: prognostic utility of quantitative diffusion-weighted MR images. AJNR Am J Neuroradiol. 2002;23:1038–48.PubMed
63.
Zurück zum Zitat Garcia G, Atallah JP Antineoplastic agents and thrombotic microangiopathy. J Oncol Pharm Pract. 2016. Garcia G, Atallah JP Antineoplastic agents and thrombotic microangiopathy. J Oncol Pharm Pract. 2016.
64.
Zurück zum Zitat Park SB, Goldstein D, Krishnan AV, et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin. 2013;63:419–37.PubMedCrossRef Park SB, Goldstein D, Krishnan AV, et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin. 2013;63:419–37.PubMedCrossRef
65.
Zurück zum Zitat Rivera E, Cianfrocca M. Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer. Cancer Chemother Pharmacol. 2015;75:659–70.PubMedPubMedCentralCrossRef Rivera E, Cianfrocca M. Overview of neuropathy associated with taxanes for the treatment of metastatic breast cancer. Cancer Chemother Pharmacol. 2015;75:659–70.PubMedPubMedCentralCrossRef
66.
Zurück zum Zitat Eckhoff L, Knoop AS, Jensen M-B, Ejlertsen B, Ewertz M. Risk of docetaxel-induced peripheral neuropathy among 1,725 Danish patients with early stage breast cancer. Breast Cancer Res Treat. 2013;142:109–18.PubMedCrossRef Eckhoff L, Knoop AS, Jensen M-B, Ejlertsen B, Ewertz M. Risk of docetaxel-induced peripheral neuropathy among 1,725 Danish patients with early stage breast cancer. Breast Cancer Res Treat. 2013;142:109–18.PubMedCrossRef
68.
Zurück zum Zitat Beijers AJM, Jongen JLM, Vreugdenhil G. Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies. Neth J Med. 2012;70:18–25.PubMed Beijers AJM, Jongen JLM, Vreugdenhil G. Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies. Neth J Med. 2012;70:18–25.PubMed
69.
Zurück zum Zitat Bhatnagar B, Gilmore S, Goloubeva O, et al. Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience. Springerplus. 2014;3:366.PubMedPubMedCentralCrossRef Bhatnagar B, Gilmore S, Goloubeva O, et al. Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings: a single-center experience. Springerplus. 2014;3:366.PubMedPubMedCentralCrossRef
70.
Zurück zum Zitat Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol. 2012;14(4):iv45–54.PubMedPubMedCentral Grisold W, Cavaletti G, Windebank AJ. Peripheral neuropathies from chemotherapeutics and targeted agents: diagnosis, treatment, and prevention. Neuro Oncol. 2012;14(4):iv45–54.PubMedPubMedCentral
71.
Zurück zum Zitat Osmani K, Vignes S, Aissi M, et al. Taxane-induced peripheral neuropathy has good long-term prognosis: a 1- to 13-year evaluation. J Neurol. 2012;259:1936–43.PubMedCrossRef Osmani K, Vignes S, Aissi M, et al. Taxane-induced peripheral neuropathy has good long-term prognosis: a 1- to 13-year evaluation. J Neurol. 2012;259:1936–43.PubMedCrossRef
72.
Zurück zum Zitat Bahl A, Oudard S, Tombal B, et al. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2013;24:2402–8.CrossRef Bahl A, Oudard S, Tombal B, et al. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2013;24:2402–8.CrossRef
73.
Zurück zum Zitat LaPointe NE, Morfini G, Brady ST, Feinstein SC, Wilson L, Jordan MA. Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy. Neurotoxicology. 2013;37:231–9.PubMedPubMedCentralCrossRef LaPointe NE, Morfini G, Brady ST, Feinstein SC, Wilson L, Jordan MA. Effects of eribulin, vincristine, paclitaxel and ixabepilone on fast axonal transport and kinesin-1 driven microtubule gliding: implications for chemotherapy-induced peripheral neuropathy. Neurotoxicology. 2013;37:231–9.PubMedPubMedCentralCrossRef
74.
Zurück zum Zitat Avan A, Postma TJ, Ceresa C, et al. Platinum-induced neurotoxicity and preventive strategies: past, present, and future. Oncologist. 2015;20:411–32.PubMedPubMedCentralCrossRef Avan A, Postma TJ, Ceresa C, et al. Platinum-induced neurotoxicity and preventive strategies: past, present, and future. Oncologist. 2015;20:411–32.PubMedPubMedCentralCrossRef
76.
Zurück zum Zitat Kropff M, Giongco-Baylon H, Hillengass J, et al. Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. Haematologica. 2012;97:784–91.PubMedPubMedCentralCrossRef Kropff M, Giongco-Baylon H, Hillengass J, et al. Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial. Haematologica. 2012;97:784–91.PubMedPubMedCentralCrossRef
77.
Zurück zum Zitat Mileshkin L, Stark R, Day B, et al. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol. 2006;24:4507–14.PubMedCrossRef Mileshkin L, Stark R, Day B, et al. Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol. 2006;24:4507–14.PubMedCrossRef
78.
Zurück zum Zitat Feyler S, Rawstron A, Jackson G, Snowden JA, Cocks K, Johnson RJ. Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study. Br J Haematol. 2007;139:429–33.PubMedCrossRef Feyler S, Rawstron A, Jackson G, Snowden JA, Cocks K, Johnson RJ. Thalidomide maintenance following high-dose therapy in multiple myeloma: a UK myeloma forum phase 2 study. Br J Haematol. 2007;139:429–33.PubMedCrossRef
79.
Zurück zum Zitat Tosi P, Zamagni E, Cellini C, et al. Neurological toxicity of long-term(>1 yr) thalidomide therapy in patients with multiple myeloma. Eur J Haematol. 2005;74:212–6.PubMedCrossRef Tosi P, Zamagni E, Cellini C, et al. Neurological toxicity of long-term(>1 yr) thalidomide therapy in patients with multiple myeloma. Eur J Haematol. 2005;74:212–6.PubMedCrossRef
80.
Zurück zum Zitat Giannini F, Volpi N, Rossi S, et al. Thalidomide-induced neuropathy: a ganglionopathy? Neurology. 2003;60:877–8.PubMedCrossRef Giannini F, Volpi N, Rossi S, et al. Thalidomide-induced neuropathy: a ganglionopathy? Neurology. 2003;60:877–8.PubMedCrossRef
81.
Zurück zum Zitat Kirchmair R, Tietz AB, Panagiotou E, et al. Therapeutic angiogenesis inhibits or rescues chemotherapy-induced peripheral neuropathy: taxol- and thalidomide induced injury of vasa nervorum is ameliorated by VEGF. Mol Ther. 2007;15:69–75.PubMedCrossRef Kirchmair R, Tietz AB, Panagiotou E, et al. Therapeutic angiogenesis inhibits or rescues chemotherapy-induced peripheral neuropathy: taxol- and thalidomide induced injury of vasa nervorum is ameliorated by VEGF. Mol Ther. 2007;15:69–75.PubMedCrossRef
82.
Zurück zum Zitat Isoardo G, Bergui M, Durelli L, et al. Thalidomide neuropathy: clinical, electrophysiological and neuoradiological features. Acta Neurol Scand. 2004;109:188–93.PubMedCrossRef Isoardo G, Bergui M, Durelli L, et al. Thalidomide neuropathy: clinical, electrophysiological and neuoradiological features. Acta Neurol Scand. 2004;109:188–93.PubMedCrossRef
83.
Zurück zum Zitat Gay F, Hayman SR, Lacy MQ, et al. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma. Blood. 2010;115:1343–50.PubMedPubMedCentralCrossRef Gay F, Hayman SR, Lacy MQ, et al. Lenalidomide plus dexamethasone versus thalidomide plus dexamethasone in newly diagnosed multiple myeloma. Blood. 2010;115:1343–50.PubMedPubMedCentralCrossRef
84.
Zurück zum Zitat Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006;354:1021–30.PubMedCrossRef Barlogie B, Tricot G, Anaissie E, et al. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med. 2006;354:1021–30.PubMedCrossRef
85.
Zurück zum Zitat Miltenburg NC, Boogerd W. Chemotherapy-induced neuropathy: a comprehensive survey. Cancer Treat Rev. 2014;40:872–82.PubMedCrossRef Miltenburg NC, Boogerd W. Chemotherapy-induced neuropathy: a comprehensive survey. Cancer Treat Rev. 2014;40:872–82.PubMedCrossRef
86.
Zurück zum Zitat Peng L, Bu Z, Ye X, Zhou Y, Zhao Q. Incidence and risk of peripheral neuropathy with nab-paclitaxel in patients with cancer: a meta-analysis. Eur J Cancer Care (Engl). 2015. doi:10.1111/ecc.12407. published online Nov 4. Peng L, Bu Z, Ye X, Zhou Y, Zhao Q. Incidence and risk of peripheral neuropathy with nab-paclitaxel in patients with cancer: a meta-analysis. Eur J Cancer Care (Engl). 2015. doi:10.​1111/​ecc.​12407. published online Nov 4.
87.
Zurück zum Zitat Chaudhry V, Eisenberger MA, Sinibaldi VJ, Sheikh K, Griffin JW, Cornblath DR. A prospective study of suramin-induced peripheral neuropathy. Brain. 1996;119(Pt 6):2039–52.PubMedCrossRef Chaudhry V, Eisenberger MA, Sinibaldi VJ, Sheikh K, Griffin JW, Cornblath DR. A prospective study of suramin-induced peripheral neuropathy. Brain. 1996;119(Pt 6):2039–52.PubMedCrossRef
88.
Zurück zum Zitat Gill JS, Windebank AJ. Suramin induced ceramide accumulation leads to apoptotic cell death in dorsal root ganglion neurons. Cell Death Differ. 1998;5(10):876–83.PubMedCrossRef Gill JS, Windebank AJ. Suramin induced ceramide accumulation leads to apoptotic cell death in dorsal root ganglion neurons. Cell Death Differ. 1998;5(10):876–83.PubMedCrossRef
89.••
Zurück zum Zitat Hershman DL, Lacchetti C, Dworkin RH, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2014;32:1941–67. Evidence-based guidance on the optimum prevention and treatment approaches in the management of CIPN in adult cancer survivors.PubMedCrossRef Hershman DL, Lacchetti C, Dworkin RH, et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2014;32:1941–67. Evidence-based guidance on the optimum prevention and treatment approaches in the management of CIPN in adult cancer survivors.PubMedCrossRef
90.
Zurück zum Zitat Pace A, Giannarelli D, Galiè E, et al. Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial. Neurology. 2010;74:762–6.PubMedCrossRef Pace A, Giannarelli D, Galiè E, et al. Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial. Neurology. 2010;74:762–6.PubMedCrossRef
91.
Zurück zum Zitat Mols F, Beijers AJM, Vreugdenhil G, Verhulst A, Schep G, Husson O. Chemotherapy-induced peripheral neuropathy, physical activity and health-related quality of life among colorectal cancer survivors from the PROFILES registry. J Cancer Surviv Res Pract. 2015;9:512–22.CrossRef Mols F, Beijers AJM, Vreugdenhil G, Verhulst A, Schep G, Husson O. Chemotherapy-induced peripheral neuropathy, physical activity and health-related quality of life among colorectal cancer survivors from the PROFILES registry. J Cancer Surviv Res Pract. 2015;9:512–22.CrossRef
92.••
Zurück zum Zitat Smith EML, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013;309:1359–67. A randomized, double-blind, placebo-controlled crossover trial demonstrating effectiveness of duloxetine in the treatment of CIPN-related pain.PubMedPubMedCentralCrossRef Smith EML, Pang H, Cirrincione C, et al. Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial. JAMA. 2013;309:1359–67. A randomized, double-blind, placebo-controlled crossover trial demonstrating effectiveness of duloxetine in the treatment of CIPN-related pain.PubMedPubMedCentralCrossRef
93.
Zurück zum Zitat Rao RD, Michalak JC, Sloan JA, et al. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer. 2007;110:2110–8.PubMedCrossRef Rao RD, Michalak JC, Sloan JA, et al. Efficacy of gabapentin in the management of chemotherapy-induced peripheral neuropathy: a phase 3 randomized, double-blind, placebo-controlled, crossover trial (N00C3). Cancer. 2007;110:2110–8.PubMedCrossRef
94.
Zurück zum Zitat Gallagher HC, Gallagher RM, Butler M, Buggy DJ, Henman MC. Venlafaxine for neuropathic pain in adults. Cochrane Database Syst Rev. 2015;8, CD011091.PubMed Gallagher HC, Gallagher RM, Butler M, Buggy DJ, Henman MC. Venlafaxine for neuropathic pain in adults. Cochrane Database Syst Rev. 2015;8, CD011091.PubMed
95.
Zurück zum Zitat Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2007;4, CD005454.PubMed Saarto T, Wiffen PJ. Antidepressants for neuropathic pain. Cochrane Database Syst Rev. 2007;4, CD005454.PubMed
96.
Zurück zum Zitat Thompson DF, Brooks KG. Systematic review of topical amitriptyline for the treatment of neuropathic pain. J Clin Pharm Ther. 2015. doi:10.1111/jcpt.12297. published online June 7. Thompson DF, Brooks KG. Systematic review of topical amitriptyline for the treatment of neuropathic pain. J Clin Pharm Ther. 2015. doi:10.​1111/​jcpt.​12297. published online June 7.
97.
Zurück zum Zitat Hearn L, Derry S, Phillips T, Moore RA, Wiffen PJ. Imipramine for neuropathic pain in adults. Cochrane Database Syst Rev. 2014;5, CD010769.PubMed Hearn L, Derry S, Phillips T, Moore RA, Wiffen PJ. Imipramine for neuropathic pain in adults. Cochrane Database Syst Rev. 2014;5, CD010769.PubMed
98.
Zurück zum Zitat Papapetrou P, Kumar AJ, Muppuri R, Chakrabortty S. Intravenous lidocaine infusion to treat chemotherapy-induced peripheral neuropathy. Case Rep. 2015;5:154–5. Papapetrou P, Kumar AJ, Muppuri R, Chakrabortty S. Intravenous lidocaine infusion to treat chemotherapy-induced peripheral neuropathy. Case Rep. 2015;5:154–5.
99.
Zurück zum Zitat Marineo G, Iorno V, Gandini C, Moschini V, Smith TJ. Scrambler therapy may relieve chronic neuropathic pain moreeffectively than guideline-based drug management: results of a pilot, randomized, controlled trial. J Pain Symptom Manag. 2012;43:87–95.CrossRef Marineo G, Iorno V, Gandini C, Moschini V, Smith TJ. Scrambler therapy may relieve chronic neuropathic pain moreeffectively than guideline-based drug management: results of a pilot, randomized, controlled trial. J Pain Symptom Manag. 2012;43:87–95.CrossRef
100.
Zurück zum Zitat Xu WR, Hua BJ, Hou W, Bao YJ. Clinical randomized controlled study on acupuncture for treatment of peripheral neuropathy induced by chemotherapeutic drugs. Zhongguo Zhen Jiu. 2010;30:457–60.PubMed Xu WR, Hua BJ, Hou W, Bao YJ. Clinical randomized controlled study on acupuncture for treatment of peripheral neuropathy induced by chemotherapeutic drugs. Zhongguo Zhen Jiu. 2010;30:457–60.PubMed
101.
Zurück zum Zitat Schroeder S, Meyer-Hamme G, Epplee S. Acupuncture for chemotherapy-induced peripheral neuropathy (CIPN): a pilot study using neurography. Acupunct Med. 2012;30:4–7.PubMedCrossRef Schroeder S, Meyer-Hamme G, Epplee S. Acupuncture for chemotherapy-induced peripheral neuropathy (CIPN): a pilot study using neurography. Acupunct Med. 2012;30:4–7.PubMedCrossRef
102.
103.
Zurück zum Zitat Saini R, Chandragouda D, Talwar V, Rajpurohit S. Grade IV myositis: a rare complication of docetaxel. J Cancer Res Ther. 2015;11:664.PubMedCrossRef Saini R, Chandragouda D, Talwar V, Rajpurohit S. Grade IV myositis: a rare complication of docetaxel. J Cancer Res Ther. 2015;11:664.PubMedCrossRef
104.
Zurück zum Zitat Orsucci D, Pizzanelli C, Alì G, et al. Nerve, muscle and heart acute toxicity following oxaliplatin and capecitabine treatment. Neuromuscul Disord NMD. 2012;22:767–70.PubMedCrossRef Orsucci D, Pizzanelli C, Alì G, et al. Nerve, muscle and heart acute toxicity following oxaliplatin and capecitabine treatment. Neuromuscul Disord NMD. 2012;22:767–70.PubMedCrossRef
105.
Zurück zum Zitat Pentsova E, Liu A, Rosenblum M, O’Reilly E, Chen X, Hormigo A. Gemcitabine induced myositis in patients with pancreatic cancer: case reports and topic review. J Neurooncol. 2012;106:15–21.PubMedCrossRef Pentsova E, Liu A, Rosenblum M, O’Reilly E, Chen X, Hormigo A. Gemcitabine induced myositis in patients with pancreatic cancer: case reports and topic review. J Neurooncol. 2012;106:15–21.PubMedCrossRef
106.
Zurück zum Zitat Bradley WG, Lassman LP, Pearce GW, Walton JN. The neuromyopathy of vincristine in man. Clinical, electrophysiological and pathological studies. J Neurol Sci. 1970;10(2):107–31.PubMedCrossRef Bradley WG, Lassman LP, Pearce GW, Walton JN. The neuromyopathy of vincristine in man. Clinical, electrophysiological and pathological studies. J Neurol Sci. 1970;10(2):107–31.PubMedCrossRef
107.
Zurück zum Zitat Truica CI, Frankel SR. Acute rhabdomyolysis as a complication of cytarabine chemotherapy for acute myeloid leukemia: case report and review of literature. Am J Hematol. 2002;70:320–3.PubMedCrossRef Truica CI, Frankel SR. Acute rhabdomyolysis as a complication of cytarabine chemotherapy for acute myeloid leukemia: case report and review of literature. Am J Hematol. 2002;70:320–3.PubMedCrossRef
108.
Zurück zum Zitat Lintermans A, Van Calster B, Van Hoydonck M, et al. Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis. Ann Oncol. 2011;22(8):1763–9.PubMedCrossRef Lintermans A, Van Calster B, Van Hoydonck M, et al. Aromatase inhibitor-induced loss of grip strength is body mass index dependent: hypothesis-generating findings for its pathogenesis. Ann Oncol. 2011;22(8):1763–9.PubMedCrossRef
109.
Zurück zum Zitat Irwin ML, Cartmel B, Gross CP, et al. Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors. J Clin Oncol. 2015;33(10):1104–11.PubMedCrossRef Irwin ML, Cartmel B, Gross CP, et al. Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors. J Clin Oncol. 2015;33(10):1104–11.PubMedCrossRef
110.
Zurück zum Zitat Batchelor TT, Taylor LP, Thaler HT, Posner JB, DeAngelis LM. Steroid myopathy in cancer patients. Neurology. 1997;48:1234–8.PubMedCrossRef Batchelor TT, Taylor LP, Thaler HT, Posner JB, DeAngelis LM. Steroid myopathy in cancer patients. Neurology. 1997;48:1234–8.PubMedCrossRef
111.
Zurück zum Zitat Roth P, Wick W, Weller M. Steroids in neurooncology: actions, indications, side-effects. Curr Opin Neurol. 2010;23:597–602.PubMedCrossRef Roth P, Wick W, Weller M. Steroids in neurooncology: actions, indications, side-effects. Curr Opin Neurol. 2010;23:597–602.PubMedCrossRef
112.
Zurück zum Zitat van Balkom RH, van der Heijden HF, van Herwaarden CL, Dekhuijzen PN. Corticosteroid-induced myopathy of the respiratory muscles. Neth J Med. 1994;45:114–22.PubMed van Balkom RH, van der Heijden HF, van Herwaarden CL, Dekhuijzen PN. Corticosteroid-induced myopathy of the respiratory muscles. Neth J Med. 1994;45:114–22.PubMed
113.
Zurück zum Zitat Da Silva JA, Jacobs JWG, Kirwan JR, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis. 2006;65:285–93.PubMedCrossRef Da Silva JA, Jacobs JWG, Kirwan JR, et al. Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data. Ann Rheum Dis. 2006;65:285–93.PubMedCrossRef
Metadaten
Titel
Chemotherapy-Related Neurotoxicity
verfasst von
Sophie Taillibert
Emilie Le Rhun
Marc C. Chamberlain
Publikationsdatum
01.09.2016
Verlag
Springer US
Erschienen in
Current Neurology and Neuroscience Reports / Ausgabe 9/2016
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-016-0686-x

Weitere Artikel der Ausgabe 9/2016

Current Neurology and Neuroscience Reports 9/2016 Zur Ausgabe

Demyelinating Disorders (DN Bourdette and M Cameron, Section Editors)

Alemtuzumab for Multiple Sclerosis

Infection (J Halperin, Section Editor)

Impact of Infection on Stroke Morbidity and Outcomes

Sleep (M Thorpy and M Billiard, Section Editors)

Sleep Disturbances in Frontotemporal Dementia

Epilepsy (CW Bazil, Section Editor)

Driving and Epilepsy: a Review of Important Issues

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Thrombektomie auch bei großen Infarkten von Vorteil

16.05.2024 Ischämischer Schlaganfall Nachrichten

Auch ein sehr ausgedehnter ischämischer Schlaganfall scheint an sich kein Grund zu sein, von einer mechanischen Thrombektomie abzusehen. Dafür spricht die LASTE-Studie, an der Patienten und Patientinnen mit einem ASPECTS von maximal 5 beteiligt waren.

Schwindelursache: Massagepistole lässt Otholiten tanzen

14.05.2024 Benigner Lagerungsschwindel Nachrichten

Wenn jüngere Menschen über ständig rezidivierenden Lagerungsschwindel klagen, könnte eine Massagepistole der Auslöser sein. In JAMA Otolaryngology warnt ein Team vor der Anwendung hochpotenter Geräte im Bereich des Nackens.

Schützt Olivenöl vor dem Tod durch Demenz?

10.05.2024 Morbus Alzheimer Nachrichten

Konsumieren Menschen täglich 7 Gramm Olivenöl, ist ihr Risiko, an einer Demenz zu sterben, um mehr als ein Viertel reduziert – und dies weitgehend unabhängig von ihrer sonstigen Ernährung. Dafür sprechen Auswertungen zweier großer US-Studien.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.